Trial Profile
A 6-Week, Multi-Centre, Double-Blind, Double-Dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2018
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary) ; Chlorpromazine
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms ESPRIT
- Sponsors AstraZeneca
- 14 May 2012 Actual patient number is 388 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 27 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.